BROFAROMINE IN ENDOGENOUS-DEPRESSION

1. Recently, a new generation of monoamine oxidase (MAO) inhibitors ha s been developed which selectively and reversibly inhibit MAO-A activi ty. 2. One of these compounds, called brofaromine, has been administer ed in subjects suffering from endogenous depression, revealing antidep ressive efficacy in a majority of them without inducing serious advers e events. 3. The results obtained so far suggest that brofaromine migh t be effective in endogenous depressed patients who failed to respond to tricyclic antidepressants.